KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Acquisitions & Divestments (2016 - 2025)

Inovio Pharmaceuticals' Change in Acquisitions & Divestments history spans 16 years, with the latest figure at $8.9 million for Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments fell 77.0% year-over-year to $8.9 million; the TTM value through Sep 2025 reached $53.8 million, down 68.92%, while the annual FY2024 figure was $158.6 million, 44.32% down from the prior year.
  • Change in Acquisitions & Divestments for Q3 2025 was $8.9 million at Inovio Pharmaceuticals, down from $10.3 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $123.1 million in Q1 2022 and bottomed at $7620.0 in Q1 2025.
  • The 5-year median for Change in Acquisitions & Divestments is $49.0 million (2023), against an average of $52.6 million.
  • The largest annual shift saw Change in Acquisitions & Divestments soared 24293.23% in 2022 before it crashed 99.99% in 2025.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $34.6 million in 2021, then surged by 186.23% to $99.1 million in 2022, then plummeted by 50.56% to $49.0 million in 2023, then dropped by 29.45% to $34.6 million in 2024, then tumbled by 74.16% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Change in Acquisitions & Divestments are $8.9 million (Q3 2025), $10.3 million (Q2 2025), and $7620.0 (Q1 2025).